| __timestamp | Ascendis Pharma A/S | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 9079000 |
| Thursday, January 1, 2015 | 9415000 | 20309000 |
| Friday, January 1, 2016 | 11504000 | 16945000 |
| Sunday, January 1, 2017 | 13482000 | 20559000 |
| Monday, January 1, 2018 | 25057000 | 29641000 |
| Tuesday, January 1, 2019 | 48473000 | 88258000 |
| Wednesday, January 1, 2020 | 76669000 | 162170000 |
| Friday, January 1, 2021 | 160180000 | 167218000 |
| Saturday, January 1, 2022 | 221227000 | 239528000 |
| Sunday, January 1, 2023 | 264410000 | 94252000 |
| Monday, January 1, 2024 | 284545000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ascendis Pharma A/S and Galapagos NV, two prominent players, have shown contrasting trends in their SG&A optimization strategies over the past decade. From 2014 to 2023, Ascendis Pharma A/S saw a staggering 4,100% increase in SG&A expenses, peaking in 2023. In contrast, Galapagos NV's SG&A costs surged by 940% until 2022, before dropping by 60% in 2023. This dramatic shift suggests a strategic pivot by Galapagos NV, potentially reallocating resources to enhance operational efficiency. Meanwhile, Ascendis Pharma A/S's consistent rise in expenses may indicate aggressive expansion efforts. As these companies navigate the complexities of the biotech landscape, their SG&A strategies will be pivotal in determining their long-term success.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Galapagos NV
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
Selling, General, and Administrative Costs: AstraZeneca PLC vs Galapagos NV
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV
Breaking Down SG&A Expenses: Mesoblast Limited vs Galapagos NV
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV